Dry AMD Market Set for Significant Transformation Through 2034, Driven by Novel Therapeutic Approaches and Rising Disease Awareness | DelveInsight

The dry age-related macular degeneration treatment market is experiencing unprecedented growth, driven by increasing disease awareness, rising prevalence of age-related eye conditions, and breakthrough therapeutic developments from major pharmaceutical companies, including Alkeus Pharmaceuticals, Cognition Therapeutics, Dobecure, Evergreen Therapeutics, InflammX Therapeutics, Lineage Cell Therapeutics, Luxa Biotechnology, Regenerative Patch Technologies, Amgen Inc., AstraZeneca, Bayer AG, Biogen, Boehringer Ingelheim, Hoffmann-La Roche, Johnson & Johnson, Novartis, and Pfizer Inc., actively pursuing innovative treatment solutions.

DelveInsight's "Dry AMD Market Insight, Epidemiology And Market Forecast - 2034" report delivers an in-depth understanding of the dry AMD treatment market, historical and forecasted epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and dry AMD market forecasts through 2034, providing crucial insights for stakeholders in the ophthalmology therapeutic area.

According to DelveInsight's analysis, the dry AMD market in the 7MM is expected to witness a major transformation by 2034, driven by enhanced understanding of disease pathogenesis, novel therapeutic mechanisms, and increasing healthcare expenditure across global markets. The market expansion is further supported by advances in diagnostic technologies that enable earlier disease detection and more precise patient stratification for targeted therapeutic interventions.

The United States represents the largest dry AMD market opportunity, supported by advanced healthcare infrastructure, favorable reimbursement environments, and high disease awareness among ophthalmologists and retinal specialists. The EU5 countries collectively represent significant market potential, with Germany, France, Italy, Spain, and the United Kingdom each contributing to overall European market growth through 2034.

Furthermore, Japan's dry AMD market reflects unique demographic characteristics with rapidly aging populations and specific regulatory pathways for ophthalmic therapeutics.

Download the Dry AMD Market report to understand which factors drive the Dry AMD therapeutic market @ https://www.delveinsight.com/sample-request/dry-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The DelveInsight report provides detailed epidemiological insights covering historical and forecasted dry AMD patient populations across the 7MM. The epidemiology section encompasses total prevalent cases of dry AMD, with segmentation into early and intermediate AMD stages, as well as late-stage conditions including neovascular AMD and geographic atrophy. This comprehensive patient population analysis helps identify regional trends and demographic patterns essential for market planning and therapeutic development strategies.

The report categorizes dry AMD patient populations across individual countries within the 7MM, providing granular insights into disease burden distribution and regional variations in prevalence rates. These epidemiological findings support pharmaceutical companies and healthcare stakeholders in understanding market opportunities and tailoring therapeutic approaches to specific geographic populations with varying disease characteristics and treatment accessibility.

Discover evolving trends in the Dry AMD patient pool forecasts @ https://www.delveinsight.com/sample-request/dry-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The report further discusses the current and evolving dry AMD treatment landscape. Currently, the dry age-related macular degeneration treatment landscape is undergoing a significant transformation. For many years, management was limited to lifestyle modifications and dietary supplements, as there were no approved pharmacologic therapies to slow disease progression.

However, in 2023, the FDA approved the first two drugs specifically for late-stage dry AMD, also known as geographic atrophy: SYFOVRE (pegcetacoplan) and IZERVAY (avacincaptad pegol). Both therapies offer hope to patients who previously had no approved options to slow vision loss. For earlier stages of dry AMD, treatment remains focused on nutritional supplementation and regular monitoring, as no approved therapies exist for these stages yet.

The most significant breakthrough in dry AMD treatment came with the FDA approval of LumiThera's Valeda Light Delivery System in November 2024. This photobiomodulation therapy represents the first FDA-authorized non-invasive treatment for vision loss in dry AMD patients. The approval was granted under the FDA's "De Novo" process, marking a historic milestone as the first treatment specifically designed to improve vision rather than merely slow disease progression.

In July 2025, the FDA granted Fast Track Designation to SAR446597, an investigational gene therapy from Sanofi intended for one-time intravitreal injection in geographic atrophy (GA), the advanced stage of dry AMD. This designation accelerates its development and regulatory review.

Furthermore, in September 2025, Luxa Biotechnology announced positive Phase 1/2 results for RPESC-RPE-4W therapy, enabling dose escalation for their cell therapy candidate in dry AMD. The company confirmed safety and tolerability, supporting further development.

In February 2025, the FDA approved an expanded label for avacincaptad pegol (Izervay), allowing flexible dosing for geographic atrophy management in AMD patients.

In January 2025, Apellis Pharmaceuticals received approval for Syfovre in Australia, making it the first and only approved treatment for geographic atrophy in Australia.

Recently, Alcon announced and completed the acquisition of LumiThera, including the FDA-cleared Valeda PBM device for dry AMD. This strategic move enables broader commercialization and access to Valeda. The merger closed in Q3 2025, confirming Alcon's commitment to advancing non-invasive dry AMD treatments.

Discover more recent advancements in the Dry AMD treatment landscape @ https://www.delveinsight.com/sample-request/dry-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

DelveInsight's pipeline analysis reveals robust clinical development activity targeting novel mechanisms of action for dry AMD treatment. Astellas' ASP7317, currently in Phase I, is a complement pathway inhibitor aimed at slowing geographic atrophy progression by modulating inflammatory cascades.

Emerging gene therapies such as Ocugen's OCU410 (Phase I/II) employ AAV vectors to deliver retinal-protective genes like RORA, while Alkeus Pharmaceuticals' ALK-001 modifies toxic vitamin A metabolites to prevent lipofuscin accumulation. Furthermore, regenerative approaches are advancing through stem cell-derived Retinal Pigment Epithelium (RPE) transplants, including Astellas' ASP7317 subretinal implants and Eyestem Research's Eyecyte-RPE therapy, showing 15-letter visual acuity gains in early trials.

These pipeline candidates demonstrate the shift toward disease modification and vision preservation strategies.

The competitive landscape includes both established ophthalmology companies and biotechnology firms, such as Alkeus Pharmaceuticals, Cognition Therapeutics (NASDAQ: CGTX), Dobecure, Evergreen Therapeutics, InflammX Therapeutics, Lineage Cell Therapeutics (NYSE: LCTX), Luxa Biotechnology, and Regenerative Patch Technologies, developing specialized therapeutic approaches for retinal diseases. Major pharmaceutical companies, such as Amgen Inc. (NASDAQ: AMGN), AstraZeneca (NASDAQ: AZN), Bayer AG (OTC: BAYRY), Biogen (NASDAQ: BIIB), Boehringer Ingelheim, Hoffmann-La Roche (OTC: RHHBY), Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), and Pfizer Inc. (NYSE: PFE), are investing significantly in dry AMD research and development, recognizing the substantial commercial opportunity and critical medical need for effective treatments.

Looking ahead, the dry AMD market is positioned for remarkable transformation driven by novel therapeutic mechanisms, improved understanding of disease biology, and personalized medicine approaches targeting specific patient subpopulations. The pipeline includes innovative therapies focusing on complement system modulation, oxidative stress reduction, and neuronal protection strategies that address fundamental pathophysiological processes underlying dry AMD progression.

As clinical research advances and regulatory pathways evolve, the dry AMD market is poised for significant growth and therapeutic innovation through 2034, potentially transforming outcomes for millions of patients affected by this sight-threatening condition.

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Dry AMD
4. Key Events
5. Epidemiology and Dry AMD Market Forecast Methodology
6. Dry AMD Market Overview at a Glance
7. Dry AMD Background and Overview
8. Dry AMD Treatment and Management
9. Dry AMD Epidemiology and Patient Population in the 7MM
10. Dry AMD Patient Journey
11. Dry AMD Marketed Therapies
12. Dry AMD Emerging Therapies
13. Dry AMD: Seven Major Market Analysis
14. Dry AMD Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Dry AMD Pipeline Insight [https://www.delveinsight.com/sample-request/dry-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr]

Dry AMD Pipeline Insight provides comprehensive insights about the Dry AMD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Dry AMD companies, including Alkeus Pharmaceuticals, Dobecure, Belite Bio, Cognition Therapeutics, Aviceda Therapeutics, Stealth BioTherapeutics, Allegro Ophthalmics, Annexon Biosciences, OliX Pharmaceuticals, and Ocugen, among others.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

This release was published on openPR.